Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.49 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.49 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921253 | 1.00 | FTO (0.49) | FTOEGLN2TLR7GRM4L3MBTL1 | |
| SCHEMBL19726532 | 0.85 | FTO (0.47) | FTOEGLN2TLR7GRM4MAPT | |
| SCHEMBL16834813 | 0.85 | FTO (0.55) | FTOEGLN2TLR7ALDH1A1PIM1 | |
| SCHEMBL1921280 | 0.85 | FTO (0.55) | FTOEGLN2TLR7ALDH1A1PIM1 | |
| SCHEMBL17902420 | 0.78 | MAOA (0.42) | FTOEGLN2TLR7GRM4 | |
| SCHEMBL17901267 | 0.78 | FTO (0.40) | FTOEGLN2TLR7MEN1KMT2A | |
| SCHEMBL20682895 | 0.78 | FTO (0.40) | FTOEGLN2TLR7MEN1KMT2A | |
| SCHEMBL17905260 | 0.78 | FTO (0.40) | FTOEGLN2TLR7MEN1KMT2A | |
| SCHEMBL108876 | 0.77 | L3MBTL1 (0.62) | FTOEGLN2TLR7L3MBTL1ALDH1A1 | |
| SCHEMBL20892686 | 0.77 | MEN1 (0.41) | L3MBTL1MEN1KMT2AAPOBEC3GALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044005-B8 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT CO LLC (PR) | 2012-12-05 | — | — | EP | claimed |
| EP-2044005-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-04-08 | — | — | EP | claimed |
| WO-2008002576-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | claimed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | claimed |
| US-12478615-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20240358691-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT COMPANY, LLC (PR) | 2024-10-31 | — | — | US | disclosed |
| US-11883386-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2023-06-29 | — | — | US | disclosed |
| EP-4095127-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2022-11-30 | — | — | EP | disclosed |
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | AKEBIA THERAPEUTICS, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| EP-3357911-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS INC (US) | 2022-05-11 | — | — | EP | disclosed |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | KREOS CAPITAL VII (UK) LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-2327696-A1 | Prolyl hydroxylase inhibitors and methods of use | Warner Chilcott Company, LLC (PR) | 2011-06-01 | — | — | EP | disclosed |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | disclosed |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. | 2010-12-30 | — | — | US | disclosed |
| EP-2044005-B1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | WARNER CHILCOTT CO LLC (PR) | 2010-10-20 | — | — | EP | disclosed |
| US-7811595-B2 | such as {[5-(3-Chloro-phenyl)-3-hydroxy-pyridine-2-carbonyl]-amino}-acetic acid methyl ester; for controlling Peripheral Vascular Disease, Coronary Artery Disease, heart failure, ischemia, and anemia | WARNER CHILCOTT COMPANY, LLC (US) | 2010-10-12 | — | — | US | disclosed |
| EP-2044005-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | The Procter and Gamble Company (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008002576-A2 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | THE PROCTER & GAMBLE COMPANY (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | THE PROCTER & GAMBLE COMPANY (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11426393-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | FTO 1298/4885EGLN2 5/4885TLR7 4774/4885 |
| US-11883386-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | FTO 1298/4885EGLN2 5/4885TLR7 4774/4885 |
| US-20240358691-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, EGLN2 | FTO 1120/4885EGLN2 3/4885TLR7 4765/4885 |
| US-20100331374-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | FTO 1298/4885EGLN2 5/4885TLR7 4774/4885 |
| US-12478615-B2 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | FTO 1298/4885EGLN2 5/4885TLR7 4774/4885 |
| US-20210137901-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | FTO 1298/4885EGLN2 5/4885TLR7 4774/4885 |
| US-20230201178-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | FTO 1298/4885EGLN2 5/4885TLR7 4774/4885 |
| US-20070299086-A1 | Prolyl hydroxylase inhibitors and methods of use | HIF1AN, EGLN3, HIF1A | FTO 1298/4885EGLN2 5/4885TLR7 4774/4885 |
| US-20100331303-A1 | PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE | HIF1AN, EGLN3, HIF1A | FTO 1298/4885EGLN2 5/4885TLR7 4774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.